These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18794088)

  • 21. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
    Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
    Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
    Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
    Almasi CE; Christensen IJ; Høyer-Hansen G; Danø K; Pappot H; Dienemann H; Muley T
    Lung Cancer; 2011 Dec; 74(3):510-5. PubMed ID: 21640427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
    J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
    Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
    Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
    Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
    Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
    Eugen-Olsen J; Gustafson P; Sidenius N; Fischer TK; Parner J; Aaby P; Gomes VF; Lisse I
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):686-92. PubMed ID: 12150480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
    Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
    Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
    Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
    J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
    Mustjoki S; Alitalo R; Stephens RW; Vaheri A
    Thromb Haemost; 1999 May; 81(5):705-10. PubMed ID: 10365741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.